Indoco Remedies has secured final USFDA approval for its generic Lacosamide oral solution, a bioequivalent of Vimpat, enabling the company to market this essential epilepsy treatment in the US from ...

Indoco Remedies receives USFDA approval to market generic Lacosamide oral solution for epilepsy treatment. Manufactured in Goa facility.

Mumbai: Indoco Remedies Ltd. has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated ...

Indoco Remedies announced final approval of the Company's Abbreviated New Drug Application (ANDA) for Lacosamide Oral Solution USP, 10 mg/mL, to market, a generic equivalent to the reference listed ...

Indoco Remedies receives US FDA final approval for its ANDA for lacosamide oral solution USP, 10 mg/mL: Our Bureau, Mumbai Friday, January 30, 2026, 14:30 Hrs [IST] Indoco Remedie ...

Lacosamide Oral Solution is used in the treatment of partial onset seizures and primary generalised tonic-clonic seizures in adults and children aged four years and above with epilepsy.

New Delhi, Jan 30 (PTI) Indoco Remedies Ltd on Friday said it has received approval from the US health regulator to market its generic version of Lacosamide oral solution used in the treatment of ...

Epilepsy surgery has been shown to be an effective treatment for patients with intractable epilepsy. The only randomized controlled trial conducted in this setting to date found a dramatic advantage ...

An estimated 60% of patients with Alzheimer's disease develop epilepsy or subclinical epileptiform activity over the course of the disease. New-onset seizures in cognitively healthy adults also ...